|
GENERAL PEDIATRICS DRUG INFORMATION
Amikacin
Aminoglycoside antibiotic
Gram negative organisms with documented resistance to other aminoglycosides
IV:
15-20 mg/kg/day divided Q12-24H
Once daily dosing is preferred except in selected cases including patients with renal impairment. May need to extend dosing interval in renal impairment.
Extend dosing interval in renal impairment. Ototoxicity and nephrotoxicity may occur, consider monitoring trough levels (<5-10 mg/L) in patients at risk for nephrotoxicity: septic shock, concurrent nephrotoxins, fluctuating renal function or extended treatment courses. Reserved for gram negative organisms with documented resistance to other aminoglycosides.
Updated: 12/21/2022
Disclaimer: This document has been created specifically for Hamilton Health Sciences (HHS) to use for its own patients and the information contained herein may not be applicable or relevant to other health care organizations. This document is for informational purposes only and is not intended to be a substitute for medical or clinical advice from a qualified health care professional. HHS makes no representations or warranties as to the accuracy of the information. This material is current only to the date listed. This material is the intellectual property of HHS and may not be shared, duplicated, or distributed further without the consent of HHS. HHS assumes no liability for the use of this information by the recipient.
| |